Tumor Hypoxia in Cancer Therapy

Methods in Enzymology

Volumn 435, Issue , 2007, Pages

  Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 METHOXYESTRADIOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; BLEOMYCIN; CHETOMIN; CISPLATIN; CYTOCHROME P450; CYTOTOXIN; DINITROBENZAMIDE MUSTARD; FLUOROURACIL; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; MISONIDAZOLE; MITOMYCIN; MONOCLONAL ANTIBODY; NITROIMIDAZOLE DERIVATIVE; PACLITAXEL; POLYPEPTIDE; PR 104; PRODRUG; QUINONE DERIVATIVE; RADIOSENSITIZING AGENT; RECOMBINANT ENZYME; TEMOZOLOMIDE; TIRAPAZAMINE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ANTHRAQUINONE DERIVATIVE; CHLORMETHINE DERIVATIVE; OXYGEN; PR-104; TRIAZINE DERIVATIVE;

ANAEROBE; ANAEROBIC BACTERIUM; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CARCINOMA; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG TARGETING; GENETIC ENGINEERING; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; IONIZING RADIATION; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; NECROSIS; NONHUMAN; OXYGEN CONCENTRATION; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TUMOR NECROSIS; ARTICLE; CELL HYPOXIA; DRUG ANTAGONISM; GENE TARGETING; GENE THERAPY; GENETICS; METABOLISM; NEOPLASM;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CYTOTOXINS; GENE TARGETING; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; OXYGEN; PRODRUGS; TRIAZINES;

EID: 39749172398     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)35015-5     Document Type: Review

References (109)

1. Anlezark G.M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., and Knox R.J. The bioactivation of 5-(Aziridin-1-YL)-2,4-dinitrobenzamide (CB 1954)-I Purification and properties of a nitroreductase enzyme from Escherichia Coli-A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44 (1992) 2289-2295
2. Batchelder R.M., Wilson W.R., Hay M.P., and Denny W.A. Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1. Br. J. Cancer Suppl. 27 (1996) S52-S56
3. Binley K., Askham Z., Martin L., Spearman H., Day D., Kingsman S., and Naylor S. Hypoxia-mediated tumour targeting. Gene Ther. 10 (2003) 540-549
4. Bridgewater J.A., Springer C.J., Knox R.J., Minton N.P., Michael N.P., and Collins M.K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A (1995) 2362-2370
5. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., and Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56 (1996) 941-943
6. Brown J.M. Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro-7-0582. Radiat. Res. 64 (1975) 633-647
7. Brown J.M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 52 (1979) 650-656
8. Brown J.M. Tumor microenvironment and the response to therapy. Cancer Biol. Ther. 1 (2002) 453-458
9. Brown J.M., and Lemmon M.J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50 (1990) 7745-7749
10. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004) 437-447
11. Burke B., Tang N., Corke K.P., Tazzyman D., Ameri K., Wells M., and Lewis C.E. Expression of HIF-1α by human macrophages: Implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol. 196 (2002) 204-212
12. Carey R.W., Holland J.F., Whang H.Y., Neter E., and Bryant B. Clostridial oncolysis in man. Europ. J. Cancer 3 (1967) 37-46
13. Chaplin D.J., Durand R.E., and Olive P.L. Acute hypoxia in tumors: Implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 12 (1986) 1279-1282
14. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res. 47 (1987) 597-601
15. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., Hussain S., Murray P.I., Searle P., Seymour L., Harris P.A., Ferry D., et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7 (2001) 2662-2668
16. Churchill-Davidson I., Foster C.A., and Thomlinson R.H. High-pressure oxygen and radiotherapy. Med. World 88 (1958) 125-128
17. Cobb L.M., Connors T.A., Elson L.A., Khan A.H., Mitchley B.C.V., Ross W.C.J., and Whisson M.E. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. 18 (1969) 1519-1527
18. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62 (2002) 3387-3394
19. Crabtree H.G., and Cramer W. The action of radium on cancer cells I. II.-Some factors determining the susceptibility of cancer cells to radium. Proc. Roy. Soc. B. 113 (1933) 238-250
20. Denekamp J., and Harris S.R. Tests of two electron-affinic radiosensitizers in vivo using regrowth of an experimental carcinoma. Rad. Res. 61 (1975) 191-203
21. Denekamp J., and Joiner M.C. The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation. Br. J. Radiol. 55 (1982) 657-663
22. Dorie M.J., and Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53 (1993) 4633-4636
23. Durand R.E. The influence of microenvironmental factors during cancer therapy. In vivo 8 (1994) 691-702
24. Engelbart K., and Gericke D. Oncolysis by clostridia V. Transplanted tumors of the hamster. Cancer Res. 24 (1964) 239-243
25. Fox M.E., Lemmon M.J., Mauchline M.L., Davis T.O., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a delivery system for cancer gene therapy: Activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 3 (1996) 173-178
26. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2 (2003) 803-811
27. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., and Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
28. Gray L.H., Conger A.D., Ebert M., Hornsey S., and Scott O.C. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Brit. J. Radiol. 26 (1953) 638-648
29. Greco O., and Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J. Cell Physiol. 187 (2001) 22-36
30. Griffiths L., Binley K., Iqball S., Kan O., Maxwell P., Ratcliffe P., Lewis C., Harris A., Kingsman S., and Naylor S. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7 (2000) 255-262
31. Hall E.J. "Radiobiology for the Radiologist." (2000), J.B. Lippincott Company, Philadelphia, PA
32. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
33. Henk J.M. Does hyperbaric oxygen have a future in radiation therapy?. Int. J. Radiat. Oncol. Biol. Phys. 7 (1981) 1125-1128
34. Heppner F., and Mose J.R. The liquefaction (oncolysis) of malignant gliomas by a nonpathogenic clostridium. Acta Neuro. 12 (1978) 123-125
35. Heppner F., Mose J., Ascher P.W., and Walter G. Oncolysis of malignant gliomas of the brain. 13th Int. Cong. Chemother. 226 (1983) 38-45
36. Hicks K.O., Pruijn F.B., Secomb T.W., Hay M.P., Hsu R., Brown J.M., Denny W.A., Dewhirst M.W., and Wilson W.R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst. 98 (2006) 1118-1128
37. Hill R.P. Experimental Radiotherapy. In: Tannock I.F., and Hill R.P. (Eds). "The Basic Science of Oncology" (1992), McGraw-Hill, Inc., Toronto, Canada 276-301
38. 2, microcirculatory function and radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 40 (1998) 943-951
39. Hill S.A., Pigott K.H., Saunders M.I., Powell M.E., Arnold S., Obeid A., Ward G., Leahy M., Hoskin P.J., and Chaplin D.J. Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Brit. J. Cancer 74 Suppl 27 (1996) S260-S263
40. Hodgkiss R.J., Roberts I.J., Watts M.E., and Woodcock M. Rapid-mixing studies of radiosensitivity with thiol-depleted mammalian cells. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 52 (1987) 735-744
41. Holthusen H. Beitrage zur biologie der strahelnwirkung. Untershungen an askarideneiern. Ptlugers Arch. f.d. ges. Physio. 187 (1921) 1-24
42. Kallman R.F. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105 (1972) 135-142
43. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., and Dewhirst M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56 (1996) 5522-5528
44. Knox R.J., Friedlos F., Jarman M., and Roberts J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(Aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(Aziridin-1-YL)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharm. 37 (1988) 4661-4669
45. Knox R.J., Boland M.P., Friedlos F., Coles B., Southan C., and Roberts J.J. The nitroreductase enzyme in Walker cells that activates 5-(Aziridin-1-YL)-2,4-dinitrobenzamide (CB 1954) to 5-(Aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37 (1988) 4671-4677
46. Koch C.J., Stobbe C.C., and Bump E.A. The effect on the Km for radiosensitization at 0° of thiol depletion by diethylmaleate pretreatment: Quantitative differences found using the radiation sensitizing agent misonidazole or oxygen. Radiat. Res. 98 (1984) 141-153
47. Kovacs M.S., Hocking D.J., Evans J.W., Siim B.G., Wouters B.G., and Brown J.M. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer 80 (1999) 1245-1251
48. Kung A.L., Wang S., Klco J.M., Kaelin W.G., and Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6 (2000) 1335-1340
49. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
50. Lanzen J., Braun R.D., Klitzman B., Brizel D., Secomb T.W., and Dewhirst M.W. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res. 66 (2006) 2219-2223
51. Le Q.T., Denko N.C., and Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Met. Rev. 23 (2004) 293-310
52. Lemmon M.L., Van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4 (1997) 791-796
53. Lemmon M.J., Elwell J.H., Brehm J.K., Mauchline M.L., N., M., Minton N.P., Giaccia A.J., and Brown J.M. Anaerobic bacteria as a gene delivery system to tumors. Proc. Am. Assoc. Cancer Res. 35 (1994) 374
54. Liu S.C., Minton N.P., Giaccia A.J., and Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy 9 (2002) 291-296
55. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., and Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62 (2002) 2478-2482
56. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., and Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
57. Malmgren R.A., and Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 15 (1955) 473-478
58. Martin J., Stribbling S.M., Poon G.K., Begent R.H., Napier M., Sharma S.K., and Springer C.J. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother. Pharmacol. 40 (1997) 189-201
59. McCarthy H.O., Yakkundi A., McErlane V., Hughes C.M., Keilty G., Murray M., Patterson L.H., Hirst D.G., McKeown S.R., and Robson T. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 10 (2003) 40-48
60. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 4 (2006) 601-605
61. Minton N.P. Clostridia in cancer therapy. Nat. Rev. Microbiol. 1 (2003) 237-242
62. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
63. Möse J.R., and Möse G. Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich tumor des Maus. Z. Krebsforsch 63 (1959) 63-74
64. Möse J.R., and Möse G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res. 24 (1964) 212-216
65. Mottram J.C. On the alteration in the sensitivity of cells towards radiation produced by cold and by anaerobiosis. Brit. J. Radiol. 8 (1935) 32-39
66. Moulder J.E., and Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev. 5 (1987) 313-341
67. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41 (1996) 31-40
68. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., Becker A., Adam M., Molls M., Dunst J., Terris D.J., Overgaard J., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77 (2005) 18-24
69. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent. Cancer Metastasis Rev. 12 (1993) 119-134
70. Patterson L.H. Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab. Rev. 34 (2002) 581-592
71. Patterson L.H., and McKeown S.R. AQ4N: A new approach to hypoxia-activated cancer chemotherapy. Br. J. Cancer 83 (2000) 1589-1593
72. Patterson L.H., and Murray G.I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8 (2002) 1335-1347
73. Patterson L.H., McKeown S.R., Ruparelia K., Double J.A., Bibby M.C., Cole S., and Stratford I.J. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br. J. Cancer 82 (2000) 1984-1990
74. Patterson A.V., Williams K.J., Cowen R.L., Jaffar M., Telfer B.A., Saunders M., Airley R., Honess D., Van Der Kogel A.J., Wolf C.R., and Stratford I.J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 9 (2002) 946-954
75. Pawelek J.M., Low K.B., and Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57 (1997) 4537-4544
76. Petry E. Zur kenntnis der degingungen der biologischen wirkung der Rontgenstrahlen III Mitteilung. Wirkung von oxydationsmitteln auf die empfindlichkeit. Biochem. Z. 135 (1923) 353-383
77. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
78. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., and Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Res. 64 (2004) 1475-1482
79. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., Borgel S.D., Carter J.P., Hewitt S.M., Shoemaker R.H., and Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64 (2004) 6845-6848
80. Riballo E., Kuhne M., Rief N., Doherty A., Smith G.C., Recio M.J., Reis C., Dahm K., Fricke A., Krempler A., Parker A.R., Jackson S.P., et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to γ-H2AX foci. Mol. Cell 16 (2004) 715-724
81. Rischin D., Peters L., Fisher R., Macann A., Denham J., Poulsen M., Jackson M., Kenny L., Penniment M., Corry J., Lamb D., McClure B., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23 (2005) 79-87
82. Romero-Ramirez L., Cao H., Nelson D., Hammond E., Lee A.H., Yoshida H., Mori K., Glimcher L.H., Denko N.C., Giaccia A.J., Le Q.T., Koong A.C., et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64 (2004) 5943-5947
83. Semenza G.L. Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med. 41 (2002) 79-83
84. Sheldon P.W., Foster J.L., and Fowler J.F. Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug. Br. J. Cancer 30 (1974) 560-565
85. Shibata T., Giaccia A.J., and Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4 (2002) 40-48
86. Shibata T., Akiyama N., Noda M., Sasai K., and Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 913-916
87. 2(1) or 3 ATA, or photons plus misonidazole. Radiat. Res. 116 (1988) 482-502
88. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., and Krissansen G.W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8 (2001) 638-645
89. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., and Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
90. Tannock I.F. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Brit. J. Cancer 22 (1968) 258-273
91. Tannock I.F. Conventional cancer therapy: Promise broken or promise delayed?. Lancet 351 Suppl 2 (1998) SII9-SII16
92. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41 (1981) 73-81
93. Thiele E.H., Arison R.N., and Boxer G.E. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res. 24 (1964) 222-233
94. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Brit. J. Cancer 9 (1955) 539-549
95. Toso J.F., Gill V.J., Hwu P., Marincola F.M., Restifo N.P., Schwartzentruber D.J., Sherry R.M., Topalian S.L., Yang J.C., Stock F., Freezer L.J., Morton K.E., et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20 (2002) 142-152
96. Trinh Q.T., Austin E.A., Murray D.M., Knick V.C., and Huber B.E. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5- fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 55 (1995) 4808-4812
97. Trotter M.J., Chaplin D.J., and Olive P.L. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Brit. J. Cancer 59 (1989) 706-709
98. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P., Talbot D., Rey A., Butler T.W., Hirsh V., Olver I., Bergman B., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol. 18 (2000) 1351-1359
99. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin. Cancer Res. 9 (2003) 1957-1971
100. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., Petrat K., Putz V., Hescheler J., and Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 17 (2003) 503-505
101. Whillans D.W., and Hunt J.W. A rapid-mixing comparison on the mechanisms of radiosensitization by oxygen and misonidazole in CHO cells. Radiat. Res. 90 (1982) 126-141
102. Williams K.J., Telfer B.A., Xenaki D., Sheridan M.R., Desbaillets I., Peters H.J., Honess D., Harris A.L., Dachs G.U., van der Kogel A., and Stratford I.J. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75 (2005) 89-98
103. Wilson W.R., Pullen S.M., Hogg A., Helsby N.A., Hicks K.O., and Denny W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 62 (2002) 1425-1432
104. Wilson W.R., Edmunds S.J., Valentine S., Gu Y., Myint H., Hicks K.O., Yang S., Atwell G.J., and Patterson A.V. Mechanism of action and antitumour activity of PR-104, a dinitrobenzamide mustard pre-prodrug that is activated selectively under hypoxia. October 3. Poster at National Cancer Research Institute Conference, Birmingham, UK (2005)
105. Wilson W.R., Pullen S.M., Degenkolbe D.M., Ferry D.M., Helsby N.A., Hicks K.O., Atwell G.J., Yang S., Denny W.A., and Patterson A.V. Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins [abstract 496]. Eur. J. Cancer Supp. 2 (2004) 151
106. Wouters B.G., and Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147 (1997) 541-550
107. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
108. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., and Lee W.W. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12 (1986) 1239-1242
109. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835